Identification of bladder cancer patients at risk for recurrence or progression: An immunohistochemical study based on the expression of metallothionein

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 71, Issue 13-14, 2008, Pages 954-959

  Hinkel, Andreas ^a   Schmidtchen, Sonja ^a   Palisaar, Rein Jueri ^a   Noldus, Joachim ^a   Pannek, Jürgen ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CISPLATIN; METALLOTHIONEIN; METHOTREXATE; MITOMYCIN C; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SURVIVAL RATE;

EID: 47349090601     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287390801989101     Document Type: Article

References (38)

1. Bahnson, R. R., Banner, B. F., Ernstoff, M. S., Lazo, J. S., Cherian, M. G., Banerjee, D., and Chin, J. L. 1991. Immunohistochemical localization of metallothionein in transitional cell carcinoma of the bladder. J. Urol. 146:1518-1520.
2. Bahnson, R. R., Becich, M., Ernstoff, M. S., Sandlow, J., Cohen, M. B., and Williams, R. D. 1994. Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. J. Urol. 152:2272-2275.
3. Cherian, M. G., Jayasurya, A., and Bay, B. H. 2003. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat. Res. 533:201-209.
4. Detre, S., Saclani Jotti, G., and Dowsett, M. 1995. A "quickscore" method for immunohistochemical semiquantitation: Validation for oestrogen receptor in breast carcinomas. J. Clin. Pathol. 48:876-878.
5. de Vere White, R. W., and Stapp, E. 1998. Predicting prognosis in patients with superficial bladder cancer. Oncology (Huntingt.) 12:1717-1726.
6. Duncan, E. L., and Reddel, R. R. 1999. Downregulation of metallothionein-IIA expression occurs at immortalization. Oncogene 18:897-903.
7. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S. C., Nichols, P. W., Skinner, D. G., Jones, P. A., and Cote, R. J. 1994. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331:1259-1264.
8. Fukuzawa, S., Hashimura, T., Sasaki, M., Yamabe, H., and Yoshida O. 1995. Nuclear morphometry for improved prediction of the prognosis of human bladder carcinoma. Cancer 76:1790-1796.
9. Haerslev, T., Jacobsen, G. K., and Zedeler, K. 1995. The prognostic significance of immunohistochemically detectable metallothionein in primary breast carcinomas. APMIS 103:279-285.
10. Hishikawa, Y., Koji, T., Dhar, D. K., Kinugasa, S., Yamaguchi, M., and Nagasue, N. 1999. Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br. J. Cancer. 81:712-720.
11. Hiura, T., Khalid, H., Yamashita, H., Tokunaga, Y., Yasunaga, A., and Shibata, S. 1998. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival. Cancer 83:2361-2369.
12. Ioachim, E. E., Charchanti. A. V., Stavropoulos, N. E., Athanassiou, E. D., Michael, M. C., and Agnantis, N. J. 2001. Localization of metallothionein in urothelial carcinoma of the human urinary bladder: An immunohistochemical study including correlation with HLA-DR antigen, p53, and proliferation indices. Anticancer Res. 21:1757-1761.
13. Joseph, M. G., Banerjee, D., Kocha, W., Feld, R., Stitt, L. W., and Cherian, M. G. 2001. Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome. Cancer 92:836-842.
14. Kotoh, S., Naito, S., Sakamoto, N., Goto, K., and Kumazawa, J. 1994. Metallothionein expression is correlated with cisplatin resistance in transitional cell carcinoma of the urinary tract. J. Urol. 152:1267-1270.
15. Malkowicz, S. B. 1997. Superficial bladder cancer: the role of molecular markers in the treatment of high-risk superficial disease. Semin. Urol. Oncol. 15:169-178.
16. Manuel, Y., Thomas, Y., and Pellegrini, O. 1992. Metallothionein and tissue damage. IARC Sci. Publ. 118:231-237.
17. Nagel, W. W., and Vallee, B. L. 1995. Cell cycle regulation of metallothionein in human colonic cancer cells. Proc. Natl. Acad. Sci. USA 92:579-583.
18. Ofner, D., Maier, H., Riedmann, B., Bammer, T., Rumer, A., Winde, G., Bocker, W., Jasani, B., and Schmid, K. W. 1994. Immunohistochemical metallothionein expression in colorectal adenocarcinoma: Correlation with tumour stage and patient survival. Virchows Arch. 425:491-497.
19. Ohshio, G., Imamura, T., Okada, N., Wang, Z. H., Yamaki, K., Kyogoku, T., Suwa, H., Yamabe, H., and Imamura, M. 1996. Immunohistochemical study of metallothionein in pancreatic carcinomas. J. Cancer Res. Clin. Oncol. 122:351-355.
20. Oikawa, S., Kurasaki, M., Kojima, Y., and Kawanishi, S. 1995. Oxidative and nonoxidative mechanisms of site-specific DNA cleavage induced by copper-containing metallothioneins. Biochemistry 34:8763-8770.
21. Ostrakhovitch, E. A., Olsson, P. E., Jiang, S., and Cherian, M. G. 2006. Interaction of metallothionein with tumor suppressor p53 protein. FEBS Lett. 580:1235-1238.
22. Saga, Y., Hashimoto, H., Yachiku, S., Tokumitsu, M., and Kaneko, S. 2002. Immunohistochemical expression of metallothionein in human bladder cancer: Correlation with histopathological parameters and patient survival. J. Urol. 168:2227-2231.
23. Saika, T., Tsushima, T., Ochi, J., Akebi, N., Nasu, Y., Matsumura, Y., and Ohmori, H. 1994. Over-expression of metallothionein and drug-resistance in bladder cancer. Int. J. Urol. 1:135-139.
24. Sauter, G., Gasser, T. C., Moch, H., Richter, J., Jiang, F., Albrecht, R., Novotny, H., Wagner, U., Bubendorf, L., and Mihatsch, M. J. 1997. DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH. Urol. Res. 25(Suppl 1):37-43.
25. Schmid, K. W., Zelger, B., Hittmair, A., Laidler, P., Jasani, B., and Böcker, W. 1992. Metallothionein-Überexpression in malignen Melanomen. Zusammenhang mit Prognose und Therapie. Verh. Dtsch. Ges. Pathol. 76:512-516.
26. Schroeder, J. J., and Cousins, R. J. 1990. Interleukin-6 regulates metallothionein gene expression and zinc metabolism in hepatocyte monolayer cell cultures. Proc. Natl. Acad. Sci. USA 87:3137-3141.
27. Sens, M. A., Somji, S., Lamm, D. L., Garrett, S. H., Slovinsky, F., Todd, J. H., and Sens, D. A. 2000. Metallothionein isoform 3 as a potential biomarker for human bladder cancer. Environ. Health Perspect. 108:413-418.
28. Siu, L. L., Banerjee, D., Khurana, R. J., Pan, X., Pflueger, R., Tannock, I. F., and Moore, M. J. 1998. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin. Cancer Res. 4:559-565.
29. Sobin, L. H., Wittekin, C. H., and International Union Against Cancer. 1997. TNM classification of malignant tumors, 5th ed. New York: Wiley.
30. Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Chatterjee, S. J., Esrig, D., Dickinson, M. G., Groshen, S., Taylor, C. R., Jones, P. A., Skinner, D. G., and Cote, R. J. 1998. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl. Cancer Inst. 15:1072-1079.
31. Tohyama, C., Suzuki, J. S., Homma, S., Karasawa, M., Kuroki, T., Nishimura, H., and Nishimura, N. 1996. Testosterone-dependent induction of metallothionein in genital organs of male rats. Biochem. J. 317:97-102.
32. Tuzel, E., Kirkali, Z., Yorukoglu, K., Mungan, M. U., and Sade, M. 2001. Metallothionein expression in renal cell carcinoma: subcellular localization and prognostic significance. J. Urol. 165:1710-1713.
33. Waalkes, M. P., Donovan, M. P., and Thomas, J. A. 1982. Cadmium-induced prostate metallothionein in the rabbit. Prostate 3:23-25.
34. Waalkes, M. P., and Goering, P. L. 1990. Metallothionein and other cadmium binding proteins: recent developments. Chem. Res. Toxicol. 3:281-288.
35. Woo, E. S., Kondo, Y., Watkins, S. C., Hoyt, D. G., and Lazo, J. S. 1996. Nucleophilic distribution of metallothionein in human tumor cells. Exp. Cell Res. 224:365-371.
36. Yamasaki, Y., Smith, C., Weisz, D., van Huizen, I., Xuan, J., Moussa, M., Stitt, L., Hideki, S., Cherian, M. G., and Izawa, J. I. 2006. Metallothionein expression as prognostic factor for transitional cell carcinoma of bladder. Urology 67:530-535.
37. Zhou, X. D., Sens, D. A., Sens, M. A., Namburi, V. B., Singh, R. K., and Garrett, S. H., Somji, S. 2006. Metallothionein-1 and -2 expression in cadmium-or arsenic-derived human malignant urothelial cells and tumor heterotransplants and as a prognostic indicator in human bladder cancer. Toxicol. Sci. 91:467-475.
38. Zlotta, A. R., Noel, J. C., Fayt, I., Drowart, A., Van Vooren, J. P., Huygen, K., Simon, J., and Schulman, C. C. 1999. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J. Urol. 161:792-798.